The forecasted Domestic General Government Health Expenditure in India from 2024 to 2028 shows a consistent increase. The values in US Dollars PPP per capita rise steadily each year from $83.14 in 2024 to $96.12 in 2028. This upward trend suggests a growing investment in health per capita, likely reflecting India's ongoing commitment to improving healthcare infrastructure and services.
In 2023, the expenditure stood at $79.98. The year-on-year percentage variations from 2024 to 2025, and 2025 to 2026 are approximately 3.9% and 3.7% respectively. The compound annual growth rate (CAGR) from 2024 to 2028 is roughly 3.7%, indicating a stable growth trajectory.
Future trends to watch for include potential impacts of economic fluctuations, healthcare policy reforms, and technological advancements in medical fields, which could further influence government health expenditure patterns.
Latest reports
US Autoimmune Disease Market Report- Q1 2025
The US autoimmune disease market in Q1 2025 is experiencing significant shifts driven by advancements in biosimilars, biologics, and innovative therapies. The focus...
China Autoimmune Disease Market Report- Q1 2025
The autoimmune disease market in China has experienced substantial growth in the first quarter of 2025, driven by significant advancements in biopharmaceutical developments,...
Japan Autoimmune Disease Market Report- Q1 2025
The first quarter of 2025 witnessed significant developments in the autoimmune disease market in Japan, driven by technological advancements and strategic collaborations that...
Germany Autoimmune Disease Market Report- Q4 2024
The fourth quarter of 2024 marked a significant period for the autoimmune disease market in Germany, driven by advancements in treatment options and...
UK Autoimmune Disease Market Report- Q1 2025
The first quarter of 2025 has seen significant developments in the Autoimmune Disease UK market, driven by advancements in personalized medicine, increasing prevalence...
South Korea Autoimmune Disease Market Report- Q1 2025
The first quarter of 2025 marks a pivotal period for the Autoimmune Disease Market in South Korea, characterized by significant economic, technological, and...
